CLINICAL TRIALS PROFILE FOR ZEPZELCA
✉ Email this page to a colleague
All Clinical Trials for ZEPZELCA
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT05042934 ↗ | Lurbinectedin With or Without Irinotecan in Treating Patients With Relapsed or High Risk Metastatic Ewing Sarcoma | Not yet recruiting | National Cancer Institute (NCI) | Phase 1/Phase 2 | 2021-09-15 | This phase Ib/II trial studies best dose and side effects of lurbinectedin and how well it works with or without irinotecan in treating patients with Ewing sarcoma that has come back (relapsed) or is high risk and has spread to other places in the body (metastatic). Lurbinectedin may decrease chemicals in the body related to Ewing sarcoma, and reducing these chemicals may make the tumor cells more sensitive to irinotecan. Chemotherapy drugs, such as irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether giving lurbinectedin with or without irinotecan may work better in treating patients with Ewing sarcoma. |
| NCT05042934 ↗ | Lurbinectedin With or Without Irinotecan in Treating Patients With Relapsed or High Risk Metastatic Ewing Sarcoma | Not yet recruiting | M.D. Anderson Cancer Center | Phase 1/Phase 2 | 2021-09-15 | This phase Ib/II trial studies best dose and side effects of lurbinectedin and how well it works with or without irinotecan in treating patients with Ewing sarcoma that has come back (relapsed) or is high risk and has spread to other places in the body (metastatic). Lurbinectedin may decrease chemicals in the body related to Ewing sarcoma, and reducing these chemicals may make the tumor cells more sensitive to irinotecan. Chemotherapy drugs, such as irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether giving lurbinectedin with or without irinotecan may work better in treating patients with Ewing sarcoma. |
| NCT05099666 ↗ | Lurbinectedin + Doxorubicin In Leiomyosarcoma | Not yet recruiting | Jazz Pharmaceuticals | Phase 1/Phase 2 | 2022-03-01 | This research study involves the study drug lurbinectedin in combination with doxorubicin. This research has two parts. The first part is being done to determine the tolerability of lurbinectedin with doxorubicin in people with soft tissue sarcoma. The second part is a randomized study to determine which is more effective at treating leiomyosarcoma, lurbinectedin with doxorubicin or lurbinectedin alone. |
| NCT05099666 ↗ | Lurbinectedin + Doxorubicin In Leiomyosarcoma | Not yet recruiting | Massachusetts General Hospital | Phase 1/Phase 2 | 2022-03-01 | This research study involves the study drug lurbinectedin in combination with doxorubicin. This research has two parts. The first part is being done to determine the tolerability of lurbinectedin with doxorubicin in people with soft tissue sarcoma. The second part is a randomized study to determine which is more effective at treating leiomyosarcoma, lurbinectedin with doxorubicin or lurbinectedin alone. |
| NCT05229588 ↗ | Lurbinectedin in Patients With Advanced Pancreatic Cancer With DNA Repair Mutations | Not yet recruiting | Jazz Pharmaceuticals | Phase 2 | 2022-03-01 | The purpose of this research is to evaluate the activity and safety of lurbinectedin in adult patients with advanced pancreatic cancer with DNA repair mutations. |
| NCT05229588 ↗ | Lurbinectedin in Patients With Advanced Pancreatic Cancer With DNA Repair Mutations | Not yet recruiting | HonorHealth Research Institute | Phase 2 | 2022-03-01 | The purpose of this research is to evaluate the activity and safety of lurbinectedin in adult patients with advanced pancreatic cancer with DNA repair mutations. |
| NCT05244239 ↗ | Palliative Radiotherapy With Lurbinectedin in Patients With Extensive Stage Small Cell Lung Cancer | Not yet recruiting | Jazz Pharmaceuticals | Phase 1 | 2022-03-26 | This phase I trial aims to determine if it is safe to use palliative radiotherapy and lurbinectedin at the same time to treat small cell lung cancer that has spread outside of the chest and that has grown after being treated with chemotherapy (extensive stage). Lurbinectedin kills tumor cells by blocks a process called transcription that small cell lung cancer relies on to survive. It also damages the deoxyribonucleic acid (DNA) of tumor cells, which is similar to the way radiation kills tumor cells. Palliative radiotherapy is a routine medical treatment for patients who have lung cancer that has spread to other parts of the body (metastatic), and is used to relieve symptoms caused by cancer or to patients from developing symptoms. This trial may help doctors understand if treating patients with lurbinectedin and palliative radiotherapy at the same time would make them both work better than either one alone or if they could cause more side effects for patients when given together. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for ZEPZELCA
Condition Name
Clinical Trial Locations for ZEPZELCA
Trials by Country
Clinical Trial Progress for ZEPZELCA
Clinical Trial Phase
Clinical Trial Sponsors for ZEPZELCA
Sponsor Name
